at the medical device company, but many on Wall Street are expecting major moves, including efforts to strengthen the balance sheet.
Shares of Boston Scientific, down 65 percent from a peak set three years ago, bounced earlier this week on news that Sam Leno, CFO of orthopedic device maker Zimmer Holdings would replace the retiring Larry Best, a hard-driving deal maker.

They said they expected him to continue the restructuring efforts already under way, and his appointment did not necessarily signal big changes.
Guidant, and analysts believe that additional restructuring efforts are likely.
potential to negatively impact the P L," Morgan Stanley analyst Glenn Reicin wrote in a research note.

Guidant acquisition, divestitures of noncore businesses and cost cutting, said David Heupel, portfolio manager of Thrivent Investment Management.
"We'd like to see those issued addressed," said Heupel, whose fund does not own Boston Scientific shares. "People want do that.

"$25 billion mistake" and the "second-worst deal ever." rod of controversy," seeing him as defiant to many on Wall position.
financials, as the capital structure is relatively complex," Reicin said.

By contrast, he described Leno is a relatively quiet figure.
little use of leverage and complex financial instruments," Reicin said. "We think Leno will bring greater discipline to the Boston Scientific's P L, but it will probably take some time for this to play out.

"
Jeff Jonas, portfolio manager at Gamco Medical Opportunities Fund, said Leno was likely to bring the same had at Zimmer.
Jonas, whose fund does not own Boston Scientific shares, arteries after angioplasty.
"We could see the balance sheet improve within six months," he said, but added that the stent market would become the market over the next two years.

resolved some issues with the U.S. Food and Drug Administration of its endosurgery business.

Added Thrivent's Heupel: "Back in the early 1990s, people thought this company wouldn't make it. It's hard to ever bet against Boston Scientific ..

. It's on our radar.